11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein‐coupled receptors

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The Concise Guide to PHARMACOLOGY 2017/18 provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point‐in‐time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.13878/full. G protein‐coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand‐gated ion channels, voltage‐gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid‐2017, and supersedes data presented in the 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature Committee of the Union of Basic and Clinical Pharmacology (NC‐IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.

          Related collections

          Most cited references106

          • Record: found
          • Abstract: not found
          • Article: not found

          GeneralizedE7(7)coset dynamics andD= 11 supergravity

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Genetics of Proteasome Diseases

            The proteasome is a large, multiple subunit complex that is capable of degrading most intracellular proteins. Polymorphisms in proteasome subunits are associated with cardiovascular diseases, diabetes, neurological diseases, and cancer. One polymorphism in the proteasome gene PSMA6 (−8C/G) is associated with three different diseases: type 2 diabetes, myocardial infarction, and coronary artery disease. One type of proteasome, the immunoproteasome, which contains inducible catalytic subunits, is adapted to generate peptides for antigen presentation. It has recently been shown that mutations and polymorphisms in the immunoproteasome catalytic subunit PSMB8 are associated with several inflammatory and autoinflammatory diseases including Nakajo-Nishimura syndrome, CANDLE syndrome, and intestinal M. tuberculosis infection. This comprehensive review describes the disease-related polymorphisms in proteasome genes associated with human diseases and the physiological modulation of proteasome function by these polymorphisms. Given the large number of subunits and the central importance of the proteasome in human physiology as well as the fast pace of detection of proteasome polymorphisms associated with human diseases, it is likely that other polymorphisms in proteasome genes associated with diseases will be detected in the near future. While disease-associated polymorphisms are now readily discovered, the challenge will be to use this genetic information for clinical benefit.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              MicroRNA-143/-145 in Cardiovascular Diseases

              MicroRNAs (miRNAs) play an essential role in the onset and development of many cardiovascular diseases. Increasing evidence shows that miRNAs can be used as potential diagnostic biomarkers for cardiovascular diseases, and miRNA-based therapy may be a promising therapy for the treatment of cardiovascular diseases. The microRNA-143/-145 (miR-143/-145) cluster is essential for differentiation of vascular smooth muscle cells (VSMCs) and determines VSMC phenotypic switching. In this review, we summarize the recent progress in knowledge concerning the function of miR-143/-145 in the cardiovascular system and their role in cardiovascular diseases. We discuss the potential role of miR-143/-145 as valuable biomarkers for cardiovascular diseases and explore the potential strategy of targeting miR-143 and miR-145.
                Bookmark

                Author and article information

                Journal
                Br J Pharmacol
                Br. J. Pharmacol
                10.1111/(ISSN)1476-5381
                BPH
                British Journal of Pharmacology
                John Wiley and Sons Inc. (Hoboken )
                0007-1188
                1476-5381
                21 October 2017
                December 2017
                21 October 2017
                : 174
                : Suppl Suppl 1 ( doiID: 10.1111/bph.v174.S1 )
                : S17-S129
                Affiliations
                [ 1 ] School of Life Sciences University of Nottingham Medical School Nottingham NG7 2UH UK
                [ 2 ] Monash Institute of Pharmaceutical Sciences and Department of Pharmacology Monash University Parkville, Victoria 3052 Australia
                [ 3 ] Clinical Pharmacology Unit University of Cambridge Cambridge CB2 0QQ UK
                [ 4 ] School of Physiology, Pharmacology and Neuroscience University of Bristol Bristol BS8 1TD UK
                [ 5 ] Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School University of Dundee Dundee DD1 9SY UK
                [ 6 ] Centre for Integrative Physiology University of Edinburgh Edinburgh EH8 9XD UK
                Article
                BPH13878 10.1111/bph.13878
                10.1111/bph.13878
                5650667
                29055040
                9f0921aa-8309-4760-b8ce-3650b83ed30c
                © 2017 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.

                This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                Page count
                Figures: 0, Tables: 122, Pages: 113, Words: 116485
                Categories
                The Concise Guide to Pharmacology 2017/18
                The Concise Guide to Pharmacology 2017/18
                Custom metadata
                2.0
                bph13878
                bph13878-hdr-0001
                December 2017
                Converter:WILEY_ML3GV2_TO_NLMPMC version:5.2.1 mode:remove_FC converted:21.10.2017

                Pharmacology & Pharmaceutical medicine
                Pharmacology & Pharmaceutical medicine

                Comments

                Comment on this article